Shares of Molecular Templates Inc. (MTEM) plummeted by 77% on Monday after the company announced plans to liquidate and wind down its operations. This decision comes after a year-long search for viable strategic alternatives yielded no positive results. While the company will explore remaining options and continue discussions with the FDA for its drug MT-0169, shareholders are unlikely to receive any value for their shares.